136 related articles for article (PubMed ID: 19164898)
21. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor.
Park JY; Zheng W; Kim D; Cheng JQ; Kumar N; Ahmad N; Pow-Sang J
Cancer Detect Prev; 2007; 31(5):359-65. PubMed ID: 18037591
[TBL] [Abstract][Full Text] [Related]
22. TWIST2: A new candidate tumor suppressor in prostate cancer.
Zhao C; Zhang W; Zhu X; Xu Y; Yang K; Wei D; Liang S; Zhao F; Zhang Y; Chen X; Sun L; Yuan H; Shi X; Wang X; Liu M; Yang F; Wang J; Yang Z
Prostate; 2019 Oct; 79(14):1647-1657. PubMed ID: 31433071
[TBL] [Abstract][Full Text] [Related]
23. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells.
Jarrard DF; Kinoshita H; Shi Y; Sandefur C; Hoff D; Meisner LF; Chang C; Herman JG; Isaacs WB; Nassif N
Cancer Res; 1998 Dec; 58(23):5310-4. PubMed ID: 9850055
[TBL] [Abstract][Full Text] [Related]
24. Tumor suppressor function of PGP9.5 is associated with epigenetic regulation in prostate cancer--novel predictor of biochemical recurrence after radical surgery.
Mitsui Y; Shiina H; Hiraki M; Arichi N; Hiraoka T; Sumura M; Honda S; Yasumoto H; Igawa M
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):487-96. PubMed ID: 22246902
[TBL] [Abstract][Full Text] [Related]
25. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
26. Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason score.
Liu W; Gong J; Hu J; Hu T; Sun Y; Du J; Sun C; Guan M; Jiang H; Lu Y
Urology; 2011 Apr; 77(4):1006.e1-7. PubMed ID: 21310466
[TBL] [Abstract][Full Text] [Related]
27. SPINT2 Deregulation in Prostate Carcinoma.
Pereira MS; de Almeida GC; Pinto F; Viana-Pereira M; Reis RM
J Histochem Cytochem; 2016 Jan; 64(1):32-41. PubMed ID: 26442953
[TBL] [Abstract][Full Text] [Related]
28. Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.
Geybels MS; Zhao S; Wong CJ; Bibikova M; Klotzle B; Wu M; Ostrander EA; Fan JB; Feng Z; Stanford JL
Prostate; 2015 Dec; 75(16):1941-50. PubMed ID: 26383847
[TBL] [Abstract][Full Text] [Related]
29. PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma.
Koch P; Petri M; Paradowska A; Stenzinger A; Sturm K; Steger K; Wimmer M
Prostate; 2009 Dec; 69(16):1751-62. PubMed ID: 19691131
[TBL] [Abstract][Full Text] [Related]
30. Functional epigenomics identifies genes frequently silenced in prostate cancer.
Lodygin D; Epanchintsev A; Menssen A; Diebold J; Hermeking H
Cancer Res; 2005 May; 65(10):4218-27. PubMed ID: 15899813
[TBL] [Abstract][Full Text] [Related]
31. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
Enokida H; Shiina H; Igawa M; Ogishima T; Kawakami T; Bassett WW; Anast JW; Li LC; Urakami S; Terashima M; Verma M; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Cancer Res; 2004 Sep; 64(17):5956-62. PubMed ID: 15342374
[TBL] [Abstract][Full Text] [Related]
32. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
Sørensen KD; Borre M; Ørntoft TF; Dyrskjøt L; Tørring N
Int J Cancer; 2008 Feb; 122(3):509-19. PubMed ID: 17943724
[TBL] [Abstract][Full Text] [Related]
33. Anti-tumoral effect of the non-nucleoside DNMT inhibitor RG108 in human prostate cancer cells.
Graça I; Sousa EJ; Baptista T; Almeida M; Ramalho-Carvalho J; Palmeira C; Henrique R; Jerónimo C
Curr Pharm Des; 2014; 20(11):1803-11. PubMed ID: 23888969
[TBL] [Abstract][Full Text] [Related]
34. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
35. Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer.
Carvalho JR; Filipe L; Costa VL; Ribeiro FR; Martins AT; Teixeira MR; Jerónimo C; Henrique R
Apoptosis; 2010 Aug; 15(8):956-65. PubMed ID: 20464497
[TBL] [Abstract][Full Text] [Related]
36. Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF-κB/DNMT1 signaling pathway.
Gao X; Mao YH; Xiao C; Li K; Liu W; Li LY; Pang J
Prostate; 2018 Jun; 78(9):682-690. PubMed ID: 29601651
[TBL] [Abstract][Full Text] [Related]
37. Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma.
Kumar SR; Bryan JN; Esebua M; Amos-Landgraf J; May TJ
BMC Cancer; 2017 Feb; 17(1):158. PubMed ID: 28235398
[TBL] [Abstract][Full Text] [Related]
38. p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation.
Bott SR; Arya M; Kirby RS; Williamson M
Prostate Cancer Prostatic Dis; 2005; 8(4):321-6. PubMed ID: 16276353
[TBL] [Abstract][Full Text] [Related]
39. AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0N promoter in prostate cancer cells.
Zhang X; Leung YK; Ho SM
Oncogene; 2007 Nov; 26(52):7346-54. PubMed ID: 17525739
[TBL] [Abstract][Full Text] [Related]
40. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
